Having trouble accessing articles? Reset your cache.

Nimotuzumab: Completed Phase II enrollment

YM BioSciences disclosed in its fiscal 2Q11 earnings that partner Daiichi Sankyo completed enrollment in a Phase II trial evaluating nimotuzumab in combination with radiation therapy,

Read the full 268 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE